A retrospective analysis of pre-existing and acquired major adverse cardiovascular events (MACE) in a real world cohort of multiple myeloma (MM) patients treated with proteasome inhibitorsFirst published 30/11/2016 Last updated 02/06/2020 EU PAS number: EUPAS16302StudyFinalised